ESMO: Pfizer, Astellas' latest Xtandi survival data may shore up prostate cancer lead over J&J

A final analysis of Pfizer and Astellas’ phase 3 ARCHES trial studying Xtandi paired with androgen deprivation (AD) therapy in men with metastatic hormone-sensitive prostate cancer found the med “significantly” prolonged their lives compared with the AD therapy alone, according to results presented at the European Society for Medical Oncology 2021 virtual congress.